Marktanalyse - Encephalopathy - Pipeline Review, H2 2016

Global Markets Direct
12.2016
54 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Encephalopathy - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy — Pipeline Review, H2 2016, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Encephalopathy.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Encephalopathy Overview 7

Therapeutics Development 8

Pipeline Products for Encephalopathy - Overview 8

Pipeline Products for Encephalopathy - Comparative Analysis 9

Encephalopathy - Therapeutics under Development by Companies 10

Encephalopathy - Therapeutics under Investigation by Universities/Institutes 11

Encephalopathy - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Encephalopathy - Products under Development by Companies 14

Encephalopathy - Products under Investigation by Universities/Institutes 15

Encephalopathy - Companies Involved in Therapeutics Development 16

Celgene Corp 16

Chiesi Farmaceutici SpA 17

Fera Pharmaceuticals LLC 18

GW Pharmaceuticals Plc 19

JS Genetics Inc 20

ProThera Biologics Inc 21

SciFluor Life Sciences LLC 22

Turing Pharmaceuticals AG 23

Zambon Company SpA 24

Encephalopathy - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

Alda-1 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

diazoxide - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GWP-42003 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

melatonin - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ORP-006 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

phenobarbitol sodium - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SF-0034 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TRP-005 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

TRP-601 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

TUR-004 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ZP-053 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Encephalopathy - Product Development Milestones 50

Featured News & Press Releases 50

Nov 16, 2015: Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies 50

Oct 23, 2015: Turing Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application and Fast Track Designation for TUR-004 50

Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51

Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54





List of Tables

Number of Products under Development for Encephalopathy, H2 2016 8

Number of Products under Development for Encephalopathy - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Encephalopathy - Pipeline by Celgene Corp, H2 2016 16

Encephalopathy - Pipeline by Chiesi Farmaceutici SpA, H2 2016 17

Encephalopathy - Pipeline by Fera Pharmaceuticals LLC, H2 2016 18

Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H2 2016 19

Encephalopathy - Pipeline by JS Genetics Inc, H2 2016 20

Encephalopathy - Pipeline by ProThera Biologics Inc, H2 2016 21

Encephalopathy - Pipeline by SciFluor Life Sciences LLC, H2 2016 22

Encephalopathy - Pipeline by Turing Pharmaceuticals AG, H2 2016 23

Encephalopathy - Pipeline by Zambon Company SpA, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33





List of Figures

Number of Products under Development for Encephalopathy, H2 2016 8

Number of Products under Development for Encephalopathy - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus